Cyclopamine

製品コードS1146 別名:11-deoxojervine

カスタマーフィードバック(4)

  • (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

    (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

  • (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

    For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

製品安全説明書

Hedgehog/Smoothened阻害剤の選択性比較

生物活性

製品説明 Cyclopamineは一種の特異性的なHedgehog信号経路拮抗剤で、TM3Hh12細胞にSmoothened (Smo)に作用する時のIC50値が46nMです。
靶点
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro試験

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 M1exZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorXTWM2OD13Lki2OlYh|ryP Mmi2V2FPT0WU
DOHH-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXyw[YxWUUN3ME25MlM2Pjh7IN88US=> MnTJV2FPT0WU
no-10 MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTlwOUCzPUDPxE1? MnvPV2FPT0WU
LS-513 NITGWItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPMWow{UUN3ME2xNU4{PTR5IN88US=> MkCzV2FPT0WU
ALL-PO Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnWOJdGUUN3ME2xNU44PzN2IN88US=> Ml\BV2FPT0WU
8-MG-BA MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7JV4ZnUUN3ME2xN{4yOTJ|IN88US=> Mkf2V2FPT0WU
RPMI-8402 MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3K3bGlEPTB;MUWuPFU{PyEQvF2= MmfRV2FPT0WU
EoL-1-cell MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LUcmlEPTB;MUiuOVk1QCEQvF2= NUnmellNW0GQR1XS
NALM-6 M1TFXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\OdIlKSzVyPUG5MlAyPjdizszN NEPFVJJUSU6JRWK=
DEL MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4m0TmlEPTB;MkCuNVQ4OSEQvF2= NUDsUZVCW0GQR1XS
SR NFOwe3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTJ|Lk[3NVUh|ryP MUDTRW5ITVJ?
697 MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfiUGhWUUN3ME2yOk43OTV3IN88US=> NVTzfHFVW0GQR1XS
COLO-829 NV3XNpp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfLTWM2OD1{Nj64OFg{KM7:TR?= MkfvV2FPT0WU
EVSA-T NIHFTYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHpW3ZIUUN3ME2yO{42PTZzIN88US=> MlvJV2FPT0WU
ATN-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTtdY1[UUN3ME2zNU4zOzJ7IN88US=> M1vhPXNCVkeHUh?=
L-363 MkL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTNzLke0OlEh|ryP MYjTRW5ITVJ?
LAMA-84 NHfQNoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTN{LkWyNVEh|ryP Mof6V2FPT0WU
NOS-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDp[JVmUUN3ME2zOE4zQTV4IN88US=> M3S4XHNCVkeHUh?=
BB30-HNC M3\IPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLYe2xKSzVyPUO0MlM{ODZizszN NXew[lNFW0GQR1XS
BC-1 MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGr2TVlKSzVyPUO3Mlk4PDZizszN MVXTRW5ITVJ?
IST-SL2 NFzoVnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fz[2lEPTB;M{iuNlI1KM7:TR?= NGq1SWpUSU6JRWK=
D-392MG NFnsbmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfUeWx{UUN3ME20NE4zOjF3IN88US=> MnnzV2FPT0WU
no-11 M3\Xb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULFcJJWUUN3ME20NE42PTJzIN88US=> NHrwNW5USU6JRWK=
LC4-1 NWjVRopHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTRyLki3NVYh|ryP NVGyPZZTW0GQR1XS
A388 MkHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTR{LkW4OFgh|ryP NYC5RlJvW0GQR1XS
NTERA-S-cl-D1 M{DoW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;a[WNKUUN3ME20Nk44ODd2IN88US=> MYPTRW5ITVJ?
CESS M3LjSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTR2LkKyN|Ih|ryP NXrtTHlsW0GQR1XS
RS4-11 M4Xp[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPoXFJKSzVyPUS5MlA6OzhizszN NHvSNZNUSU6JRWK=
MS-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTlOYVQUUN3ME21NE46OzVzIN88US=> NIHCXXFUSU6JRWK=
CTV-1 NVfMO2ozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\USoJkUUN3ME21NU4xPzRizszN MX3TRW5ITVJ?
D-502MG M4nxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUixcmhRUUN3ME21NU43OjdzIN88US=> NHfWbHVUSU6JRWK=
ML-2 NI\BblBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUT2SlJDUUN3ME21Nk46OTl3IN88US=> NWLLPZpGW0GQR1XS
SK-NEP-1 MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;4TWM2OD13Mz6zPVI{KM7:TR?= M3\VSnNCVkeHUh?=
LOXIMVI MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\HOmpKSzVyPUWzMlU5QDRizszN NGPXd49USU6JRWK=
DJM-1 NFvPW5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWq1UnhTUUN3ME21Ok4{OzlzIN88US=> MXfTRW5ITVJ?
GI-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnPWpdKSzVyPUW2MlYyPDlizszN MVHTRW5ITVJ?
IST-MES1 NX3oOW8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXZ[FJlUUN3ME22NE42PDl|IN88US=> NFztN25USU6JRWK=
MV-4-11 Mo[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPCTWM2OD14MD62OVM5KM7:TR?= NIP5clhUSU6JRWK=
OVCAR-4 M2jrZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrJfWdKSzVyPU[zMlU3PTdizszN MkXDV2FPT0WU
KE-37 NWTSUpNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXNfZVKSzVyPU[2MlI3PjhizszN M{W3SnNCVkeHUh?=
D-542MG Ml3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PtR2lEPTB;NkiuOFE{PSEQvF2= M1H3UnNCVkeHUh?=
MHH-PREB-1 NV3GVZR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGWy[2JKSzVyPUeyMlg1PDFizszN NWfGWlF4W0GQR1XS
MRK-nu-1 MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoD5TWM2OD15Mz60O|A2KM7:TR?= MXvTRW5ITVJ?
D-247MG M2DKTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnkTWM2OD15Mz61OFQzKM7:TR?= M{G2NHNCVkeHUh?=
OCI-AML2 NHHR[ZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLwT2MxUUN3ME23Ok46OzZ7IN88US=> M33yb3NCVkeHUh?=
LP-1 MnrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGf0XIlKSzVyPUiyMlg4OzFizszN NWHicZE1W0GQR1XS
HCC1599 M1TSVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTh2LkK4N|ch|ryP NYC3WlczW0GQR1XS
KARPAS-45 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\XUlVSUUN3ME24OE43QTl{IN88US=> NVXpO4FSW0GQR1XS
BE-13 NVnW[nhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPyTWM2OD17OT6wOFc4KM7:TR?= MkDxV2FPT0WU
GCIY NY\QOVY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\qNFFKSzVyPUm5MlA6PTRizszN NVS5SWp2W0GQR1XS
BV-173 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHFfYFyUUN3ME2xNFAvOzJ3IN88US=> NFjaR5BUSU6JRWK=
LB2518-MEL NWC1Z5IyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHHTWM2OD1zMECuO|g6KM7:TR?= MXjTRW5ITVJ?
KS-1 NWPwN4tST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYiwZY9HUUN3ME2xNFEvPjN7IN88US=> MoThV2FPT0WU
MOLT-16 M2LpTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHITWM2OD1zMESuPVg3KM7:TR?= NXf0U|ZYW0GQR1XS
NCI-H1770 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jt[GlEPTB;MUC4Mlc5PCEQvF2= NHLO[5pUSU6JRWK=
NCI-H82 NFTrXGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XMcWlEPTB;MUGwMlk4PiEQvF2= MnjuV2FPT0WU
NCCIT MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTOTIZGUUN3ME2xNVIvPTJ7IN88US=> NEPmOW5USU6JRWK=
KALS-1 MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnjTWM2OD1zMUWuPVQyKM7:TR?= M3foNHNCVkeHUh?=
LB2241-RCC M4j5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEmwcWVKSzVyPUGxOk43PzlizszN M{fyTnNCVkeHUh?=
HH MmDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{S0e2lEPTB;MUG3MlM6PSEQvF2= NHHJOoJUSU6JRWK=
HD-MY-Z NF7uTplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFzOD60PFgh|ryP MVrTRW5ITVJ?
EB-3 M1e2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTF{Mz6wPVQh|ryP M4TnN3NCVkeHUh?=
BL-70 MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;jTWM2OD1zMkOuNVI4KM7:TR?= M4O3TXNCVkeHUh?=
K-562 NFPEUWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTF{Nj6yOFUh|ryP NVL6OnE3W0GQR1XS
HT-144 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HEWmlEPTB;MUOzMlE3PCEQvF2= NILMepFUSU6JRWK=
PF-382 NFvne|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LmRWlEPTB;MUO0MlM3OSEQvF2= NXS2coZtW0GQR1XS
RPMI-8226 M1TZXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fFVGlEPTB;MUO1MlA1PSEQvF2= MorxV2FPT0WU
NCI-H1355 NIPGR29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTF|NT61PFch|ryP M1e4d3NCVkeHUh?=
LXF-289 NWmxTFc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13vfWlEPTB;MUO5Mlc5OSEQvF2= Mnq1V2FPT0WU
NCI-H69 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPJe3FmUUN3ME2xOFIvQTN{IN88US=> NVfrW3FDW0GQR1XS
SK-MEL-1 NHjjNG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPLVIVmUUN3ME2xOFcvOTNizszN M3LxeXNCVkeHUh?=
KARPAS-299 NV;WVFVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTF2OT6xNkDPxE1? NIiyfmdUSU6JRWK=
GB-1 M1vGPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[1SY5rUUN3ME2xOFkvOzJ{IN88US=> MXPTRW5ITVJ?
CMK NVSxR4VST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:wW3VKSzVyPUG0PU42OTVizszN NXvn[GhpW0GQR1XS
MPP-89 NEHn[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTF3Nj6wN|Uh|ryP Mn7xV2FPT0WU
KU812 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF4MT65NFIh|ryP MXjTRW5ITVJ?
REH NH;C[HBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDFSmdRUUN3ME2xOlIvOTJ3IN88US=> NW\K[|JuW0GQR1XS
NEC8 Ml7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfUTWM2OD1zNkWuNFI3KM7:TR?= NI\pPYRUSU6JRWK=
KP-N-YS MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTheohKSzVyPUG2PE4{QTVizszN NYHrV2VbW0GQR1XS
Ramos-2G6-4C10 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWniS|F{UUN3ME2xOlkvQTF3IN88US=> MkWwV2FPT0WU
Becker MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonTTWM2OD1zN{SuNVgh|ryP NXL6eoNjW0GQR1XS
LB647-SCLC M2\z[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfKTWM2OD1zN{WuPFQ2KM7:TR?= M3PIOnNCVkeHUh?=
LU-139 NFPrVpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjZdmhKSzVyPUG3PE4xOTlizszN MVXTRW5ITVJ?
QIMR-WIL MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LnRmlEPTB;MUe5MlY1PiEQvF2= M{LIPHNCVkeHUh?=
NCI-H1395 M4XHbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXITWM2OD1zN{muPVk3KM7:TR?= NG\q[XJUSU6JRWK=
NOMO-1 NIPBWpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\5WmlEPTB;MUiyMlg2KM7:TR?= MXzTRW5ITVJ?
GI-ME-N NH\oRVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfGSZhpUUN3ME2xPFcvQTZ7IN88US=> NVHMZlVzW0GQR1XS
KMS-12-PE MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLtO3VKSzVyPUG4PU4zPzNizszN NFvrfZVUSU6JRWK=
Daudi Mmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;1bGlEPTB;MUmxMlEzQCEQvF2= MXXTRW5ITVJ?
LB996-RCC NH;pOpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;XPHFXUUN3ME2xPVEvPjl7IN88US=> NXeyXpcyW0GQR1XS
NCI-H2107 M2CxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XBcWlEPTB;MUmzMlc{QSEQvF2= M{T0TXNCVkeHUh?=
SK-PN-DW NYfW[YU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTF7ND63NVkh|ryP MoL0V2FPT0WU
MC-CAR M373dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrRRYNKSzVyPUKwNk4zPTNizszN NV\1cGZXW0GQR1XS
SNB75 NXXkcXZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrnUoRKSzVyPUKyNU46PCEQvF2= NE\5bXpUSU6JRWK=
ES4 NHW3VJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[yfI9KUUN3ME2yNlMvPzh|IN88US=> NHHhUGJUSU6JRWK=
KARPAS-422 NXv0dmZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTJ{OD6zOVIh|ryP NWPPfmI6W0GQR1XS
NCI-H1648 M2TJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TVNmlEPTB;MkK5MlQ5QSEQvF2= MoTUV2FPT0WU
ES6 NFPCOlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LZTmlEPTB;MkO5MlQ{KM7:TR?= NXu1eGpuW0GQR1XS
KNS-81-FD M3TxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorCTWM2OD1{NEGuNVk4KM7:TR?= M2nlV3NCVkeHUh?=
JAR MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXIVI46UUN3ME2yOVYvOjJ3IN88US=> MX3TRW5ITVJ?
NB1 NYTueYhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHIZ3JKSzVyPUK2NE42OTZizszN NF7SdllUSU6JRWK=
D-336MG NV\1SmhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\jc2pKSzVyPUK2NE43QThizszN MXrTRW5ITVJ?
BC-3 Mo\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;oVmlEPTB;Mk[1MlE4QCEQvF2= M1LUUXNCVkeHUh?=
HCC2218 NEG0NYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LlPWlEPTB;Mk[2MlQyPSEQvF2= MXnTRW5ITVJ?
TE-9 NW[zZ492T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUOySlhCUUN3ME2yOlYvPjJ5IN88US=> NWrpWm5JW0GQR1XS
LB1047-RCC MoD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfac4pKSzVyPUK2Ok44PTNizszN MXjTRW5ITVJ?
CTB-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHXXHJKUUN3ME2yOlkvQTd|IN88US=> MWjTRW5ITVJ?
NB7 NGO1[XhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33LUWlEPTB;MkexJO69VQ>? MljRV2FPT0WU
ST486 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXUZlhkUUN3ME2yO|cvPDF{IN88US=> NY\yfVdEW0GQR1XS
HCC1187 NUjaOolpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJ6Mj64NVEh|ryP NH;RV|FUSU6JRWK=
NCI-SNU-16 M3vCXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\GTWM2OD1{OESuNlQ5KM7:TR?= Moq4V2FPT0WU
COR-L279 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXLSnRKSzVyPUK5NU42QDRizszN NYHocoU3W0GQR1XS
ES8 M2\WZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTJ7ND6xPFIh|ryP NFHITGhUSU6JRWK=
U-698-M MmHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrvVoR2UUN3ME2yPVgvOjR|IN88US=> NHz0fWlUSU6JRWK=
HEL NUj3SVdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnX2TWM2OD1|MEmuNVQ6KM7:TR?= MXXTRW5ITVJ?
KINGS-1 NFfxNIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP4SWxKSzVyPUOxNE43PzRizszN M37ORnNCVkeHUh?=
KY821 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDzTWM2OD1|M{[uOVk2KM7:TR?= M1PKe3NCVkeHUh?=
MZ1-PC NWPadlFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjHOIdKSzVyPUO0OU43OThizszN MlzoV2FPT0WU
LS-411N M{H4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfieIhKSzVyPUO1OE43PiEQvF2= NFm0fVNUSU6JRWK=
SIG-M5 MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPVR4dKUUN3ME2zOVkvPzh{IN88US=> M2OzO3NCVkeHUh?=
HT M1n4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTN4Nz63NVEh|ryP MlHsV2FPT0WU
HC-1 NI\YVpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXSUnpKSzVyPUO2O{44QDdizszN NUH6U|lXW0GQR1XS
NCI-H1694 NXKyd|ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLtPHkzUUN3ME2zO|IvQTN2IN88US=> NHrRfnZUSU6JRWK=
BB65-RCC Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTN5Nj6yOFUh|ryP NWnwdWl4W0GQR1XS
HAL-01 M4\DW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvl[ZRHUUN3ME2zO|kvQDN6IN88US=> MUTTRW5ITVJ?
ARH-77 NUPEVZlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIr3U4NKSzVyPUO5OE4xODhizszN MmrRV2FPT0WU
MZ7-mel NVm4RZpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTN7Nz6yN|Mh|ryP Mn22V2FPT0WU
SIMA M2W4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTRyMz65N|Mh|ryP MUXTRW5ITVJ?
DG-75 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml30TWM2OD12MUWuOlk5KM7:TR?= NXvUc3g4W0GQR1XS
HUTU-80 NUXvSZhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXsNHFKSzVyPUSxPU4yQDVizszN M{HGOnNCVkeHUh?=
KNS-42 NXfE[4V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFm2OYVKSzVyPUSyOU45OTVizszN Moq4V2FPT0WU
SH-4 NGrYRm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWO1c5Z7UUN3ME20NlcvPTZ3IN88US=> NVvzNnBnW0GQR1XS
L-540 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTR|MT6wN|Eh|ryP NUjyRpFQW0GQR1XS
NB10 NIfsXoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInlNVlKSzVyPUS0NU4zOzRizszN Ml\jV2FPT0WU
ES1 M2W0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrSZ|VKSzVyPUS1Nk44PTNizszN MXPTRW5ITVJ?
KMOE-2 NGPudWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHv4eXJKSzVyPUS1Ok44OTFizszN NV7kdYRKW0GQR1XS
MC116 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnVS4pKSzVyPUS1PE4yOTZizszN NIHucG9USU6JRWK=
RCC10RGB NHrWcmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;wfWlEPTB;NE[wMlAxPSEQvF2= NXPJU29SW0GQR1XS
RL95-2 M2XXfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTR4MD6yN|ch|ryP MUDTRW5ITVJ?
Raji MmrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3xTWxKSzVyPUS2PE4yPDNizszN MWjTRW5ITVJ?
CAS-1 NFPI[o5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmGwTWM2OD12N{KuNFc{KM7:TR?= M3jHVHNCVkeHUh?=
Calu-6 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M364PGlEPTB;NEe1MlI3PSEQvF2= MUjTRW5ITVJ?
KG-1 NV7ETHBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTuSo9OUUN3ME20O|gvPDRizszN M37pdnNCVkeHUh?=
LB771-HNC NWfjOXd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTR6Mj6yN|Ih|ryP MYLTRW5ITVJ?
ACN M3nseWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1u4bWlEPTB;NEmzMlU6QSEQvF2= MknYV2FPT0WU
KM12 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTR7Nj61PFkh|ryP MnfZV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo試験 Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

プロトコル(参考用のみ)

キナーゼアッセイ:[1]
+ 展開

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
細胞アッセイ: [2]
+ 展開
  • 細胞株: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • 濃度: Dissolved in DMSO, final concentration 3 μM
  • 反応時間: 4 days
  • 実験の流れ: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (参考用のみ)
動物実験:[2]
+ 展開
  • 動物モデル: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • 製剤: Dissolved in DMSO, and diluted in saline
  • 投薬量: 50 mg/kg/day
  • 投与方法: Subcutaneous injection
    (参考用のみ)

溶解度 (25°C)

体外 DMF 10 mg/mL (24.29 mM) warming
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO <1 mg/mL
体内 10% DMSO+30% PEG 300+5% Tween 80+ddH2O 1mg/mL

* <1 mg/mlは製品が微弱に溶解する或いは溶解しないことを示します。
* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 411.62
化学式

C27H41NO2

CAS No. 4449-51-8
保管
in solvent
別名 11-deoxojervine

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    How to reconstitute the compound for in vivo use in mice?

  • 回答:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened信号経路図

Hedgehog/Smoothened Inhibitors with Unique Features

相関Hedgehog/Smoothened製品

Tags: Cyclopamineを買う | Cyclopamine ic50 | Cyclopamine供給者 | Cyclopamineを購入する | Cyclopamine費用 | Cyclopamine生産者 | オーダーCyclopamine | Cyclopamine化学構造 | Cyclopamine分子量 | Cyclopamine代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID